Potential genetic predisposition for anthracycline-associated cardiomyopathy in families with dilated cardiomyopathy

OBJECTIVE: Anthracyclines are successfully used in cancer treatment, but their use is limited by their cardiotoxic side effects. Several risk factors for anthracycline-associated cardiomyopathy (AACM) are known, yet the occurrence of AACM in the absence of these known risk factors suggests that othe...

Descripción completa

Detalles Bibliográficos
Autores principales: Wasielewski, Marijke, van Spaendonck-Zwarts, Karin Y, Westerink, Nico-Derk L, Jongbloed, Jan D H, Postma, Aleida, Gietema, Jourik A, van Tintelen, J Peter, van den Berg, Maarten P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Heart Failure and Cardiomyopathies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195921/
https://www.ncbi.nlm.nih.gov/pubmed/25332820
http://dx.doi.org/10.1136/openhrt-2014-000116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195921/
https://www.ncbi.nlm.nih.gov/pubmed/25332820
http://dx.doi.org/10.1136/openhrt-2014-000116

Ejemplares similares